Loading cancer entity…
Loading cancer entity…
Clinical trials
10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,643)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 |
| clinicaltrials |
| NCT00066248 | Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment | completed | Phase 2 | 70 | University of South FloridaOTHER | 3 | Feb 3, 2014 | clinicaltrials |
| NCT02049580 | Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas | unknown | Phase 2 | 47 | Istituto Clinico HumanitasOTHER | 1 | Jan 30, 2014 | clinicaltrials |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01884441 | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | unknown | Phase 2 | 59 | Armando Santoro, MDOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00070447 | Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 5 | Jan 28, 2014 | clinicaltrials |
| NCT00727831 | Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 1 / Phase 2 | 4 | University College, LondonOTHER | 1 | Jan 27, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT01037478 | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma(SAPHIRE) | completed | Phase 2 | 37 | 4SC AGINDUSTRY | 3 | Jan 16, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT00084695 | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | unknown | Phase 2 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00258336 | Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | unknown | Phase 2 | 56 | FavrilleINDUSTRY | 1 | Jan 10, 2014 | clinicaltrials |
| NCT01016990 | Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia | unknown | Phase 2 | 52 | Auxilio Mutuo Cancer CenterOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT01307592 | Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma | unknown | Phase 2 | 70 | Auxilio Mutuo Cancer CenterOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT01210287 | Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP(IHBVRL) | unknown | Phase 2 / Phase 3 | 110 | Fudan UniversityOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00003163 | Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | unknown | Phase 2 | 10 | Medical College of WisconsinOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00008307 | Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders | unknown | Phase 2 | 52 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT02027220 | Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00656812 | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT01933282 | MESA Treatment for NK/T Cell Lymphoma(MTN) | unknown | Phase 2 | 100 | Air Force Military Medical University, ChinaOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00040690 | Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia | completed | Phase 2 | 120 | Medical Research CouncilOTHER_GOV | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00042913 | Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma | unknown | Phase 2 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00071955 | Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Genitope CorporationINDUSTRY | 2 | Dec 19, 2013 | clinicaltrials |
| NCT00002481 | Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | unknown | Phase 2 | — | St. Luke's Medical CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00002557 | Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides | unknown | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00007839 | Beta Alethine in Treating Patients With Low-Grade Lymphoma | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00008164 | Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia | unknown | Phase 2 | 30 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00014664 | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | unknown | Phase 2 | — | PDL BioPharma, Inc.INDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00026429 | Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | unknown | Phase 2 | — | Pharmatech OncologyINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00030589 | Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma | unknown | Phase 2 | — | MillennixINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00041379 | Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00053092 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma | completed | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 2 | Dec 18, 2013 | clinicaltrials |
| NCT00818961 | Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 2 | 36 | Northside Hospital, Inc.OTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01090973 | Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Dec 10, 2013 | clinicaltrials |
| NCT00003942 | Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 15 | SystemixINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00005959 | Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma | unknown | Phase 2 | — | AmgenINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00185445 | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | completed | Phase 2 | 62 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00311129 | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL | completed | Phase 2 | 41 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00688883 | Fludara (Oral) Phase II Study for Indolent Lymphoma | completed | Phase 2 | 52 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00373906 | Velcade in MALT Lymphoma Patients | completed | Phase 2 | 16 | Medical University of ViennaOTHER | 0 | Nov 27, 2013 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
Data updated 24 days agoSource updated Feb 11, 2014source: clinicaltrials